Overview

Establishing Interprofessional Clinical Pathways to Prevent Pediatric RSV

Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.

Start Activity

Format

Train the Trainer

Time to Complete

2.75 hr(s).

Release Date

April 15, 2025

Expires On

April 15, 2026

According to the CDC, up to 3% of children in their first year of life are hospitalized due to respiratory syncytial virus (RSV) each year, making it the leading cause of hospitalization among infants in the US. In addition, although prematurity and certain health problems increase the risk for severe RSV, most children hospitalized for RSV in the US have no underlying health conditions or history of preterm birth.

To prevent severe RSV disease in infants, available guidance recommends immunization with nirsevimab for all infants aged <8 months born during or entering their first RSV season (generally October through March), ideally during the birth hospitalization. However, with the availability of this novel preventive approach as well as the availability of a maternal RSV vaccine, many clinicians may have questions surrounding optimal RSV prevention strategies.

To support translation and implementation of the latest recommendations into routine clinical practice, this training program, modeled on the CDC Training of Trainers approach, provides learners with the tools and resources to facilitate peer-to-peer learning with their interprofessional clinical teams.

This educational activity is designed for pediatricians, family practice physicians, NPs and PAs in these settings, neonatologists, hospital pharmacists, and other HCPs who support preventive health practices in children. Other clinicians who may benefit from this education include obstetricians and midwives.

RSV is a common pathogen that infects nearly all children by the age of 2 years. It is the most common cause of bronchiolitis and pneumonia in infants, and each year leads to approximately 2.1 million outpatient visits, 58,000-80,000 hospitalizations, and an estimated 100-300 deaths among children younger than age 5. Unfortunately, preventive options for pediatric RSV have been limited due to challenges in vaccine development. Consequently, passive immunization of infants via monoclonal antibodies (palivizumab and nirsevimab) and maternal vaccination are the current methods for RSV prevention. As strategies for RSV prevention continue to evolve and new recommendations are introduced, healthcare providers may be challenged to remain up to date on recent evidence for the practical application of therapies in clinical practice. This educational program will provide healthcare providers with the knowledge to apply changing RSV epidemiologic patterns, risk factors for RSV, and available and emerging options for RSV prevention within daily practice and protect their most vulnerable patients.

As a result of participating in this educational activity, clinicians should be able to:
• Review RSV prevalence and associated lower respiratory tract infections and hospitalizations in infants
• Evaluate the safety and efficacy data of novel long-acting monoclonal antibody therapies for the prevention of pediatric RSV
• Implement strategies to improve passive immunization rates and mitigate the impact of RSV disease

• RSV epidemiology, risk factors, and disease burden

• Current recommendations for RSV prevention and emerging options
o Maternal RSV vaccine
o RSV monoclonal antibodies for passive immunization
o Real-world effectiveness of RSV monoclonal antibodies
o Emerging options for RSV prevention
o Current guidelines and recommendations

• Implementing RSV prevention programs
o RSV prevention in the US
o Large-scale RSV prevention: experience in Spain

• Strategies for optimizing infant RSV prophylaxis through education and communication

This educational activity is presented in collaboration with Rush University Medical Center and Academy for Continued Healthcare Learning (ACHL).

Supported by an educational grant from Sanofi US.

1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker

Joseph Domachowske, MD, FAAP, FPIDS
Professor of Pediatrics
Professor of Microbiology and Immunology
Department of Pediatrics
SUNY Upstate Medical University
Syracuse, NY

Kaitlyn Rivard, PharmD

Clinical Pharmacist, Infectious Diseases, Vaccines, and Public Health

Cleveland Clinic

Cleveland, OH

Susan Nelson MSN, RN, CPN (Nurse Planner/Peer Reviewer)

Education Quality Coordinator

Chair RUSH Nursing Documentation Committee

RUSH Department of Professional Nursing Practice

Chicago, IL

It is the policy of the Interprofessional Continuing Education office at RUSH to ensure that its CE activities are independent, free of commercial bias. Therefore, we manage all financial relationships associated with accredited continuing education activities. RUSH asks everyone who has the ability to control or influence the content of an educational activity to disclose information about all of their financial relationships with ineligible companies within the prior 24 months. An ineligible company is an entity whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. There is no minimum threshold; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies. Individuals must disclose regardless of their view of the relevance of relationships to education. Mechanisms are in place to identify and mitigate any potential conflicts of interest prior to the planning, implementation, or evaluation of the continuing education activity. If a financial relationship is identified for the person in control of content, conflict mitigation strategies will be used to mitigate the financial relationship before they assume their role.

The following financial relationships have been provided:

Joseph Domachowske, MD, FAAP, FPIDS

Consultant: Shionogi, Inc.

Grants/Research: Glaxo Smith Kline, Moderna, Pfizer, Sanofi, Shionogi, Inc.

Independent Contractor: Glaxo Smith Kline, Moderna, Sanofi, Shionogi, Inc.

Kaitlyn Rivard, PharmD

Advisor: Pfizer

Consultant: Wolters Kluwer

Susan Nelson MSN, RN, CPN

No financial relationships to disclose

Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: Clesrovimab is not approved for the prevention of RSV infection.

Rush University Medical Center and the Office of Interprofessional Continuing Education staff members, ACHL staff members, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.

This activity will take up to 2.75 hours to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

The CPE credits will be posted in the NABP profile within 30 days of participation.

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this Enduring Material for a maximum of 2.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Rush University Medical Center designates this Enduring Material for a maximum of 2.75 nursing contact hour(s).

Rush University Medical Center designates this application-based activity for a maximum of 2.75 contact hour(s) for pharmacists. ACPE Universal Activity Number: JA0000275-0000-25-081-H06-P

Laurie Novoryta
lnovoryta@achlcme.org

Overview

Establishing Interprofessional Clinical Pathways to Prevent Pediatric RSV

Program Description

Intended Audience

Activity Purpose

Learning Objectives

Meeting Schedule

Provider Information

Supporter Information

Hardware and Software Requirement

Faculty

Faculty Disclosure

Staff Disclosure

Disclaimer

Method of Participation

Accreditation and Credit Designation

Program Manager

Related Activities